Aclarion Expands Clinical Trial for AI-Powered Low Back Pain Diagnostic Tool to New Jersey

Aclarion, Inc. has expanded its Clinical Utility and Economic trial to New Jersey, adding Dr. Justin Kubeck as the second participating surgeon to study how frequently the AI-powered Nociscan tool influences treatment plans for chronic low back pain patients. This multi-center study follows the recent addition of Dr. John Keller in Michigan, with Aclarion anticipating more spine surgeons will join in coming months to build a comprehensive dataset demonstrating Nociscan's impact on clinical decision-making for payers.

The trial expansion addresses a major health concern affecting approximately 266 million people globally. Nociscan represents the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine, potentially revolutionizing diagnosis and treatment planning. Dr. Kubeck emphasized Nociscan's role as an invaluable decision support tool when evaluating diagnosis and treatment, highlighting its potential to enhance existing diagnostic protocols.

Nociscan's unique approach utilizes chemical biomarkers associated with disc pain, objectively quantifying these biomarkers through proprietary algorithms to identify potential pain sources. When combined with other diagnostic tools, the platform provides critical insights into pain location that could lead to more targeted and effective treatments. Ryan Bond, Chief Strategy Officer at Aclarion, underscored the importance of real-world evidence in driving early payer coverage decisions for emerging diagnostic tools like Nociscan, with the trial's rapid expansion expected to accelerate data gathering.

For the healthcare industry, the CLUE trial represents a significant advancement in chronic low back pain management. By providing more accurate information about pain sources, this technology could reduce unnecessary procedures and improve patient outcomes through more precise treatments. As the trial progresses, results could have far-reaching implications for both patients and providers, potentially establishing Nociscan as a standard tool in spine care if it consistently influences treatment decisions.

The New Jersey expansion marks an important milestone in Aclarion's validation efforts for Nociscan's clinical utility and economic impact. As more sites join the study at https://www.aclarion.com, the healthcare community will monitor how this AI-driven approach might reshape chronic low back pain diagnosis and treatment. The technology's potential to transform management approaches for this widespread condition makes the trial's findings particularly significant for future healthcare delivery.